BUCHANG PHARMA(SH:603858)2023-04-27 16:00Financial Performance - The company's operating revenue for 2022 was approximately ¥14.95 billion, a decrease of 5.15% compared to ¥15.76 billion in 2021[16]. - The net profit attributable to shareholders for 2022 was approximately -¥1.66 billion, representing a decline of 228.51% from a profit of ¥1.29 billion in 2021[16]. - The company reported a basic earnings per share of -¥1.4980 for 2022, a decrease of 228.52% from ¥1.1656 in 2021[17]. - The total assets at the end of 2022 were approximately ¥21.95 billion, down 8.48% from ¥23.99 billion at the end of 2021[16]. - The net assets attributable to shareholders decreased by 14.30% to approximately ¥12.36 billion at the end of 2022, compared to ¥14.42 billion at the end of 2021[16]. - The company reported quarterly revenues of ¥3.20 billion, ¥3.90 billion, ¥4.21 billion, and ¥3.65 billion for Q1, Q2, Q3, and Q4 of 2022 respectively[19]. - The net profit attributable to shareholders in Q4 2022 was -¥2.92 billion, significantly impacting the annual performance[19]. - The company reported non-recurring gains and losses totaling CNY 71,863,342.83 in 2022, down from CNY 98,651,544.67 in 2021[20]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 9.60 per 10 shares, totaling RMB 1,061,800,939.20, based on a total share capital of 1,106,042,645 shares as of December 31, 2022[4]. - There are no plans for capital reserve conversion into share capital or issuance of bonus shares in the current profit distribution plan[4]. - The company has proposed a three-year shareholder dividend return plan for 2022-2024, indicating a commitment to shareholder value[105]. Audit and Compliance - The company has received a standard unqualified audit report from Xinyong Zhonghe Accounting Firm[3]. - The board of directors has confirmed that all members attended the board meeting, ensuring the integrity of the annual report[2]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[5]. - The company has not indicated any significant changes in its operational strategy or market expansion plans in the current report[5]. - The company has not disclosed any violations of decision-making procedures regarding external guarantees[5]. - The company has not faced any penalties from securities regulatory agencies in the past three years[119]. - The company has not reported any significant changes in accounting policies that would impact its financial status or operational results[178]. Research and Development - The company applied for 51 new patents and successfully obtained 56 patents, including 20 invention patents in 2022[25]. - The company is actively expanding its product line, with 12 biological products under development, some of which have entered clinical phases I or III[25]. - The company is focusing on expanding its market presence in the cardiovascular and gynecological medication sectors, which are projected to grow due to increasing demand[31]. - The company is actively engaged in R&D across various fields, including traditional Chinese medicine, chemical drugs, and biological products, with 12 biological products currently in development, some in clinical phases I or III[47]. - The company has established a robust R&D model combining independent innovation and external technical cooperation[76]. - The company is committed to addressing unmet medical needs, particularly in chronic diseases such as Alzheimer's and diabetes[79]. Market and Competitive Landscape - The overall revenue of China's pharmaceutical manufacturing industry in 2021 was CNY 3,243.18 billion, with a year-on-year growth of 19.1%[27]. - The profit of the pharmaceutical manufacturing industry in 2021 reached CNY 687.63 billion, a year-on-year increase of 67.3%[27]. - The company is positioned to benefit from national policies promoting traditional Chinese medicine, which is expected to enhance its market presence internationally[66]. - The company is exploring strategic partnerships to accelerate the development and commercialization of its new products[78]. - The company is focused on modernizing traditional Chinese medicine through the application of advanced production techniques and evidence-based medicine[98]. Environmental and Social Responsibility - The company invested 1,053.80 million RMB in environmental protection during the reporting period[147]. - The company has established a comprehensive internal control system, with no significant deficiencies reported during the period[143]. - The company has achieved administrative approvals for multiple environmental protection projects, ensuring compliance with environmental regulations[156]. - Total charitable contributions amounted to CNY 11.6945 million, with CNY 4.014 million in cash donations and CNY 7.6805 million in material donations[166]. - The company emphasizes its commitment to social responsibility and sustainable development, although it does not publish a separate ESG report[166]. Governance and Management - The company has established a governance structure compliant with relevant laws, ensuring independent operation of the board and management[103]. - The company has maintained a stable leadership team, with most executives serving since at least 2012[109]. - The total remuneration for all directors, supervisors, and senior management in 2022 amounted to 15.1765 million yuan[118]. - The company has a clear succession plan, with several executives holding dual roles in different subsidiaries[109]. - The company has not reported any significant changes in shareholding among its directors and executives during the reporting period[107]. Financial Management and Investments - The company has engaged in non-principal guaranteed floating income financial management, with amounts of 10,000,000.00 RMB, 95,000,000.00 RMB, and 100,000,000.00 RMB from different banks[192]. - The company reported a total of 1.1 billion RMB in structured deposit products, with an average interest rate of 2.85% across various banks[193]. - The company plans to continue expanding its financial product offerings, focusing on structured deposits and derivatives[193]. - The company has successfully recovered all principal amounts from structured deposits, totaling approximately 1.1 billion RMB[193]. - The company has established partnerships with multiple banks to diversify its financial product offerings and enhance market presence[195].